SCHEMBL1345429

SCHEMBL1345429

NC(=O)c1cccc(-c2ccc(CNCc3ccccc3)nc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 3/20 0.49
FYN P06241 3/20 0.49
CHEK2 O96017 2/20 0.49
CDK1 P06493 2/20 0.49
FES P07332 2/20 0.49
ROS1 P08922 2/20 0.49
FER P16591 2/20 0.49
AXL P30530 2/20 0.49
FLT4 P35916 2/20 0.49
KDR P35968 2/20 0.49
FLT3 P36888 2/20 0.49
MAPK9 P45984 2/20 0.49
LIMK1 P53667 2/20 0.49
ROCK1 Q13464 2/20 0.49
NTRK3 Q16288 2/20 0.49
PKN2 Q16513 2/20 0.49
MARK2 Q7KZI7 2/20 0.49
AURKB Q96GD4 2/20 0.49
SLK Q9H2G2 2/20 0.49
STK17A Q9UEE5 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1345818 0.90 OPRM1 (0.49) FLT1FYNCHEK2CDK1FES
SCHEMBL1347900 0.85 CNR1 (0.55) OPRM1OPRD1OPRK1HDAC8CFD
SCHEMBL1345827 0.81 CYP11B1 (0.55) FLT1FYNCHEK2CDK1FES
SCHEMBL1347785 0.81 FYN (0.45) FLT1FYNCHEK2CDK1FES
SCHEMBL12650844 0.77 HDAC1 (0.50) FLT1FYNCHEK2CDK1FES
SCHEMBL1345801 0.77 HDAC6 (0.43) FLT1FYNCHEK2CDK1FES
SCHEMBL1788221 0.77 OPRM1 (0.54) CDC7AURKAROCK2PIM1CDK2
SCHEMBL1347867 0.77 OPRM1 (0.62) ROCK1OPRM1OPRD1OPRK1CNR1
SCHEMBL3341545 0.77 OPRM1 (0.62) ROCK1OPRM1OPRD1OPRK1CNR1
SCHEMBL13929187 0.76 ERN1 (0.52) FLT1FLT3CSF1RCNR1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US claimed
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US disclosed
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US disclosed
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US disclosed
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2010-10-21 US disclosed
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2010-10-21 US disclosed
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2010-10-21 US disclosed
WO-2009030962-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS OPRM1, OPRL1, OPRD1 FLT1 2060/4885FYN 2403/4885CHEK2 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.